Drugs / 90-Yttrium Ibritumomab tiuxetan
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02366663 | Jan 2015 → Oct 2016 | diffuse large B-cell lymphoma | City of Hope Medical Center | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 90-Yttrium Ibritumomab tiuxetan | “Radiation: 90-Yttrium Ibritumomab tiuxetan” NCT02366663 ↗ |
| Route | Intravenous | “0.4 mCi/kg given IV” NCT02366663 ↗ |